News|Articles|July 7, 2026

Q2 2026 Recap: Hepatology News & Updates

Catch up on Q2 hepatology headlines, including the historic FDA approval of bulevirtide for hepatitis delta, new data on bepirovirsen for HBV, and more.

The second quarter of 2026 marked a pivotal period in hepatology, with historic regulatory milestones and promising late-stage clinical data accelerating progress in chronic viral liver diseases. From the first US Food and Drug Administration (FDA)-approved therapy for hepatitis delta to continued momentum toward a functional cure for hepatitis B, the quarter highlighted meaningful advances in areas of longstanding unmet need.